Home › Funds › Handelsbanken Fonder AB › VRTX

Handelsbanken Fonder AB position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

Handelsbanken Fonder AB reported holding 221,078 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$115.6M, representing 0.32% of its reported portfolio and ranking #49 among its reported holdings. Handelsbanken Fonder AB has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)221.08K sh
Reported value held$115.58M
Portfolio Weight0.32%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Handelsbanken Fonder AB's VRTX position evolved

Handelsbanken Fonder AB first disclosed a stake in VRTX in Q3 2023 at 282,153 shares (US$98.1M). The position peaked in Q2 2024 at 416,381 shares, worth US$195.2M. Across 13 filings, Handelsbanken Fonder AB increased the stake 6 time(s), trimmed it 5 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 221,078 shares valued at US$115.6M — an increase of 2,786 shares quarter over quarter.. Notable position changes include a 54% increase in Q2 2024 (shares were roughly flat over the following quarter), a 28% trim in Q4 2024 (shares rose 20% over the following quarter), a 30% trim in Q1 2025 (shares fell 8% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 282.15K $98.12M New
Q4 2023 260.27K $105.90M Reduce
Q1 2024 270.69K $113.15M Add
Q2 2024 416.38K $195.17M Add
Q3 2024 411.51K $191.39M Reduce
Q4 2024 296.04K $119.21M Reduce
Q1 2025 207.65K $100.67M Reduce
Q2 2025 214.29K $95.40M Add
Q3 2025 214.76K $84.11M Hold
Q4 2025 216.33K $98.08M Add
Q1 2026 220.85K $98.62M Add
Q2 2026 218.29K $108.43M Reduce
Q3 2026 221.08K $115.58M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has Handelsbanken Fonder AB held VRTX?

Handelsbanken Fonder AB has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Handelsbanken Fonder AB's current position in VRTX?

As of Q3 2026, Handelsbanken Fonder AB holds 221.08K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $115.58M, representing 0.32% of its reported portfolio and ranking #49.

Has Handelsbanken Fonder AB been buying or selling VRTX?

In the latest 13F filing (Q3 2026), Handelsbanken Fonder AB increased its position in VRTX. The position peaked in Q2 2024 at 416.38K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.